


# Journal Pre-proof

A large-scale biobank and more genome-wide association studies of cardiovascular disease are needed in Portugal

Rui Providencia



PII: S0870-2551(25)00127-1

DOI: <https://doi.org/doi:10.1016/j.repc.2025.04.002>

Reference: REPC 2431

To appear in: *Revista Portuguesa de Cardiologia*

Please cite this article as: Providencia R, A large-scale biobank and more genome-wide association studies of cardiovascular disease are needed in Portugal, *Revista Portuguesa de Cardiologia* (2025), doi: <https://doi.org/doi:10.1016/j.repc.2025.04.002>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2025 Published by Elsevier España, S.L.U. on behalf of Sociedade Portuguesa de Cardiologia.

A large-scale biobank and more genome-wide association studies of cardiovascular disease are needed in Portugal

Um biobanco em grande escala e mais estudos de associação do genoma das doenças cardiovasculares são necessários em Portugal

Rui Providencia<sup>1,2</sup>

1- Institute of Health Informatics Research, University College London, London, United Kingdom

2- Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom

E-mail address: r.providencia@ucl.ac.uk (R. Providência)

Twitter / X : @rui\_providencia

Nearly 20 years ago, following the completion of the Human Genome Project and advances in high-throughput genotyping technologies, the first genome-wide association studies (GWAS) were published [1]. GWAS identify associations between genetic variants (single nucleotide polymorphisms [SNPs]) and phenotypical traits using an agnostic approach. GWAS became more common with the development of SNP arrays.

Among their many potential applications, GWAS findings help (i) discover potential drug targets [2], (ii) develop or improve risk prediction models [3–4], and (iii) refine population sub-phenotyping, enabling the paradigm of personalized medicine and the tailoring of prevention and treatment based on genetic risk [5].

Progress in the field has been exponential, driven by a dramatic reduction in the cost of genotyping using high-density SNP arrays over the past 20 years, now priced at less than €50 per sample. Additionally, the power of discovery has significantly increased as studies have expanded beyond small cohorts to include large international consortia and nation-scale biobanks [6].

Genome-wide association studies of Portuguese cohorts are scarce [7] and there is reduced collaboration in international consortia. Despite being largely underexplored at national level, the GENes in MAdeira and CORonary Disease (GENEMACOR) study is a solid example of a national cohort assessing the impact of genetic variants in cardiovascular outcomes. This cohort has provided invaluable and landmark contributions to the cardiovascular field [8-9]. In this issue of the Portuguese Journal of Cardiology, Sá et al., assessed a cohort of 1284 asymptomatic GENEMACOR participants without coronary artery disease using coronary artery calcium score. The authors determined which of the 33 genetic variants were independently associated

with coronary artery calcification: *PHACTR1 rs1332844*, a downstream regulator of the endothelin-1 gene, *CDKN2B-AS1 rs4977574*, an epigenetic regulator, and *MTHFD1L rs6922269*, involved in de novo thymidylate biosynthesis, were the identified candidates [10].

More cohorts with biological samples for GWAS should be established nationally. The creation of a large-scale Portuguese biobank should be a number one priority for health research in the coming years. GWAS have predominantly focused on individuals of European descent, resulting in significant disparities in genetic research, and potential issues regarding generalizability of findings. Therefore, it is important that individuals with African and South American ancestry are well-represented in this project. This is of paramount importance for advancing our understanding not only of coronary artery disease, heart failure, and atrial fibrillation, but also of the often-overlooked rheumatic heart disease, which still causes 345,000 deaths annually. Insights from the East London Genes & Health cohort [11], which addresses the underrepresentation of South Asian individuals in genetic research and explores potential contributors to the increased cardiometabolic risk in this population, will be valuable.

Conflicts of Interest: none

Funding: RP is supported by the UCL BHF Research Accelerator AA/18/6/34223, NIHR grant NIHR129463 and UKRI/ERC/HORIZON 10103153 Aristoteles.

Acknowledgements: none

## References

1. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, et al. Complement factor H polymorphism in age-related macular degeneration. *Science*. 2005 Apr 15;308(5720):385-9. doi: 10.1126/science.1109557.
2. Kukendrarajah K, Farmaki AE, Lambiase PD, Schilling R, Finan C, Floriaan Schmidt A, et al. Advancing drug development for atrial fibrillation by prioritising findings from human genetic association studies. *EBioMedicine*. 2024 Jul;105:105194. doi: 10.1016/j.ebiom.2024.105194.
3. Mendonça MI, Henriques E, Borges S, Sousa AC, Pereira A, Santos M, et al. Genetic information improves the prediction of major adverse cardiovascular events in the GENEMACOR population. *Genet Mol Biol*. 2021 Jun 11;44(2):e20200448. doi: 10.1590/1678-4685-GMB-2020-0448.
4. Temtem M, Mendonça MI, Gomes Serrão M, Santos M, Sá D, Sousa F, et al. Predictive improvement of adding coronary calcium score and a genetic risk score to a traditional risk model for cardiovascular event prediction. *Eur J Prev Cardiol*. 2024 Apr 18;31(6):709-715. doi: 10.1093/eurjpc/zwae005.
5. O'Sullivan JW, Raghavan S, Marquez-Luna C, Luzum JA, Damrauer SM, Ashley EA, et al. Polygenic Risk Scores for Cardiovascular Disease: A Scientific Statement From the American Heart Association. *Circulation*. 2022 Aug 23;146(8):e93-e118. doi: 10.1161/CIR.0000000000001077.

6. Roselli C, Surakka I, Olesen MS, Sveinbjornsson G, Marston NA, Choi SH, et al. Meta-analysis of genome-wide associations and polygenic risk prediction for atrial fibrillation in more than 180,000 cases. *Nat Genet.* 2025 Mar 6. doi: 10.1038/s41588-024-02072-3.
7. Abrantes P, Santos MM, Sousa I, Xavier JM, Francisco V, Krug T, Sobral J, Matos M, Martins M, Jacinto A, Coiteiro D, Oliveira SA. Genetic Variants Underlying Risk of Intracranial Aneurysms: Insights from a GWAS in Portugal. *PLoS One.* 2015 Jul 17;10(7):e0133422. doi: 10.1371/journal.pone.0133422.
8. Santos MR, Mendonça MI, Temtem M, Sá D, Sousa AC, Freitas S, et al. Transcription factor 21 gene and prognosis in a coronary population. *Rev Port Cardiol.* 2023 Nov;42(11):907-913. doi: 10.1016/j.repc.2023.02.014.
9. Mendonça MI, Pereira A, Monteiro J, Sousa JA, Santos M, Temtem M, et al. Impact of genetic information on coronary disease risk in Madeira: The GENEMACOR study. *Rev Port Cardiol.* 2023 Mar;42(3):193-204. doi: 10.1016/j.repc.2022.01.009.
10. Sá D, Mendonça MI, Serrão M, Sousa F, Abreu G, Henriques E, et al. Unraveling the genetic basis of subclinical atherosclerosis: Early genetic detection can improve cardiovascular prevention. *Rev Port Cardiol.* 2025 Mar 6:S0870-2551(25)00070-8. doi: 10.1016/j.repc.2025.01.003.
11. Finer S, Martin HC, Khan A, Hunt KA, MacLaughlin B, Ahmed Z, et al. Cohort Profile: East London Genes & Health (ELGH), a community-based population genomics and health study in British Bangladeshi and British Pakistani people. *Int J Epidemiol.* 2020;49(1):20-21i. doi: 10.1093/ije/dyz174.